RecruitingPhase 1NCT06859710
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy
Sponsor
University of California, Los Angeles
Enrollment
30 participants
Start Date
Nov 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research is to assess the impact of CBD on the effects of THC.
Eligibility
Min Age: 21 YearsMax Age: 55 Years
Inclusion Criteria7
- Male or non-pregnant and non-lactating females aged 21-55 years
- Report cannabis use 1-7 days per week over the month prior to screening
- Not currently seeking treatment for their cannabis use
- History of inhaled cannabis use
- Have a Body Mass Index from 18.5 - 34 kg/m2
- Able to perform all study procedures
- Must be using a contraceptive (hormonal or barrier methods)
Exclusion Criteria10
- Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
- Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
- Report using other illicit drugs in the prior 4 weeks
- Current pain
- Pregnancy
- Currently enrolled in another research protocol
- Not using a contraceptive method (hormonal or barrier methods)
- Insensitivity to the cold water stimulus of the Cold Pressor Test
- Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
- Not able to speak and read English
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPlacebo
Vaporized Placebo
DRUGTHC
Vaporized THC (20 mg)
DRUGCBD 20 mg
Vaporized CBD (20 mg)
DRUGCBD 40 mg
Vaporized CBD (40 mg)
DRUGCBD 80 mg
Vaporized CBD (80 mg)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06859710
Related Trials
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055118 locations
Testing the Pain Clinical Practice Guideline
NCT0585899611 locations
Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study
NCT075810802 locations
Clinical and Scientific Assessment of Pain and Painful Disorders
NCT027070291 location
Options for Pain Management Using Nonpharmacological Strategies
NCT055637921 location